HC Wainwright & Co. Reiterates Buy on IO Biotech, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on IO Biotech (NASDAQ:IOBT) and maintained a $12 price target.
August 14, 2024 | 11:58 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on IO Biotech and maintained a $12 price target.
The reiteration of a Buy rating and the maintenance of a $12 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100